Global Nasal Polyps Treatment Market, By Type (Ethmoidal Polyp, Antrochoanal Polyp, Others), Related Diseases (Chronic Sinusitis, Cystic Fibrosis (CF), Allergic Fungal Sinusitis (AFS), Others), Treatment (Pharmacological Therapies, Surgeries), Complications (Obstructive Sleep Apnea, Sinus Infections, Others), Drug Class (Corticosteroids, Antibiotics, Leukotriene Inhibitors, Others), Diagnosis (Nasal Endoscopy, Blood Test, Allergy Tests, Others), Treatment (Medication, Surgery, Others), Medication (Nasal Corticosteroids, Medication to Treat Nasal Polyps and Chronic Sinusitis, Others), Route of Administration (Oral, Injectable, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Nasal Polyps Treatment Market Analysis and Size
The rapid increasing geriatric population that are more vulnerable for development of nasal polyps and increasing prevalence of diseases such as asthma, chronic rhinosinusitis, nasal polyps, and allergic rhinitis across the globe is expected to accelerate the market growth in the forecast period. Furthermore, growing screening for diagnosis of asymptomatic diseases like nasal polyps and rising awareness about the disease and its complications will further carve the way for the growth of the market. However, low healthcare expenditure in some countries is projected to restraint the market growth rate. In addition, the growing research and development activities and development of minimally-invasive surgical treatments and therapies are likely to create various new opportunities that will impact this global nasal polyps treatment market growth in the forecast period of 2023 to 2030.
Data Bridge Market Research analyses that the global nasal polyps treatment market which was USD 2,718.74 million in 2022, is expected to reach USD 8,243.69 million by 2030, and is expected to undergo a CAGR of 5.6% during the forecast period of 2023 to 2030. “Ethmoidal Polyp” dominates the type segment of the global nasal polyps treatment market owing to the high prevalence of this type of nasal polyps. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nasal Polyps Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Ethmoidal Polyp, Antrochoanal Polyp, Others), Related Diseases (Chronic Sinusitis, Cystic Fibrosis (CF), Allergic Fungal Sinusitis (AFS), Others), Treatment (Pharmacological Therapies, Surgeries), Complications (Obstructive Sleep Apnea, Sinus Infections, Others), Drug Class (Corticosteroids, Antibiotics, Leukotriene Inhibitors, Others), Diagnosis (Nasal Endoscopy, Blood Test, Allergy Tests, Others), Treatment (Medication, Surgery, Others), Medication (Nasal Corticosteroids, Medication to Treat Nasal Polyps and Chronic Sinusitis, Others), Route of Administration (Oral, Injectable, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Sanofi (France), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson Services, Inc., (U.S.), Pfizer Inc. (U.S.), Novartis International AG (Switzerland), GSK plc (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Cipla Ltd. (India), Mylan N.V. (U.S.), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
Nasal polyps are noncancerous growths that develop in the lining of the nasal passages or sinuses. They are soft, painless, and usually tear-shaped or grape-like in appearance. Nasal polyps are typically associated with chronic inflammation of the nasal and sinus tissues, often resulting from conditions such as chronic rhinosinusitis, asthma, allergies, or cystic fibrosis. Nasal polyps can vary in size, ranging from small and barely noticeable to larger growths that can obstruct the nasal passages and sinuses. Treatment options for nasal polyps may include medications such as corticosteroids (nasal sprays or oral), antihistamines, or antibiotics. In some cases, surgical removal of the polyps may be necessary.
Global Nasal Polyps Treatment Market Dynamics
Drivers
- The Upsurge in the Prevalence of Asthma, Chronic Rhinosinusitis, Nasal Polyps, and Allergic Rhinitis across the Globe
Surging prevalence of increasing prevalence of diseases such as asthma, chronic rhinosinusitis, nasal polyps, and allergic rhinitis all around the globe is one of the major factors responsible for fostering growth in the market value. Growing number of different types of diseases, rising awareness about the diseases are all responsible for boosting the market growth rate.
- Research and Development Proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the pharmaceutical drugs and various diagnosis methods will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the integration of advanced technologies in the healthcare facilities is also bolstering the market growth rate.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Expansion of the Pharmaceutical Industry
The pharmaceuticals industry is experiencing growth due to various factors, including advancements in device development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the global nasal polyps treatment market.
-
Government Investments on Healthcare Infrastructure
The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative market growth opportunities. Also, high return on investments assured by the research activities will also work in the favor of the market.
Restraints/Challenges
- Rising Competition
The global nasal polyps treatment market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.
-
High Cost associated with Drug Development and Distribution
The cost of drug development and its distribution is very high in the market. Healthcare systems and payers face cost pressures, and there is a growing demand for cost-effective solutions. Manufacturers need to balance the development of innovative implants with affordability to meet market demands.
This global nasal polyps treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nasal polyps treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October 2021, Sanofi announced positive results from a Phase 3 trial evaluating Dupixent (dupilumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant reduction in nasal polyp size and improved nasal congestion and sense of smell
- In September 2021, AstraZeneca announced that the European Commission approved Fasenra (benralizumab) as an add-on maintenance treatment for severe eosinophilic nasal polyps in adult patients
Global Nasal Polyps Treatment Market Scope
The global nasal polyps treatment market is segmented on the basis of type, related diseases, treatment, complication, drug class, diagnosis, treatment, medication, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Ethmoidal Polyp
- Antrochoanal Polyp
- Others
Related Diseases
- Chronic Sinusitis
- Cystic Fibrosis (CF)
- Allergic Fungal Sinusitis (AFS)
- Others
Treatment
- Pharmacological Therapies
- Surgeries
- Medication
- Others
Complications
- Obstructive Sleep Apnea
- Sinus Infections
- Others
Drug Class
- Corticosteroids
- Antibiotics
- Leukotriene Inhibitors
- Others
Diagnosis
- Nasal Endoscopy
- Blood Test
- Allergy Tests
- Others
Medication
- Nasal Corticosteroids
- Medication to Treat Nasal Polyps
- Chronic Sinusitis
- Others
Route of Administration
- Oral
- Injectable
- Others
End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Global Nasal Polyps Treatment Market Regional Analysis/Insights
The global nasal polyps treatment market is analysed and market size insights and trends are provided by country, type, related diseases, treatment, complication, drug class, diagnosis, treatment, medication, route of administration, end user and distribution channel as referenced above.
The countries covered in the global nasal polyps treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global nasal polyps treatment market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth in the global nasal polyps treatment market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global nasal polyps treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global nasal polyps treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global nasal polyps treatment market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Nasal Polyps Treatment Market Share Analysis
The global nasal polyps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global nasal polyps treatment market.
Some of the major players operating in the global nasal polyps treatment market are:
- Abbott (U.S.)
- Sanofi (France)
- AstraZeneca (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson & Johnson Services, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis International AG (Switzerland)
- GSK plc (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Cipla Ltd. (India)
- Mylan N.V. (U.S.)
- Merck KGaA (Germany)
SKU-